Scott Dietzen
Known title: DirectorCIK: 0001651908
Associated companies
Transaction History
| P | ▲ Buy | Grant | 3,515 | $0 | 6/10/2026 | View on chart |
| P | ▼ Sell | Other | 12,811 | $0 | 6/1/2026 | View on chart |
| P | ▼ Sell | Other | 12,811 | $0 | 6/1/2026 | View on chart |
| P | ▲ Buy | Grant | 4,735 | $0 | 6/11/2025 | View on chart |
| P | ▲ Buy | Grant | 4,268 | $0 | 6/12/2024 | View on chart |
| P | ▼ Sell | Open Market | 73,500 | $3.9M | 4/12/2024 | View on chart |
| P | ▼ Sell | Open Market | 73,500 | $3.9M | 4/12/2024 | View on chart |
| P | ▼ Sell | Open Market | 132,990 | $7.0M | 4/4/2024 | View on chart |
| P | ▼ Sell | Open Market | 137,590 | $7.4M | 4/4/2024 | View on chart |
| P | ▼ Sell | Open Market | 1,961 | $107K | 4/4/2024 | View on chart |
| P | ▲ Buy | Grant | 8,543 | $0 | 6/14/2023 | View on chart |
| P | ▲ Buy | Grant | 9,097 | $0 | 6/15/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Everpure Q2 revenues up 38%, shares fall on broader S&P 500 weakness
Everpure reported a 38% surge in Q2 revenues, prompting questions about whether this growth momentum can be sustained. Despite the strong top-line results, the stock fell alongside other S&P 500 names like RUM Group and Kyndryl during the recent trading session. The company's high valuation, reflected in a trailing P/E of 173.1, may make the stock sensitive to broader market sentiment and volatility.
Everpure Q2 revenues up 38%, shares fall on broader S&P 500 weakness. Everpure reported a 38% surge in Q2 revenues, prompting questions about whether this growth momentum can be sustained. Despite the strong top-line results, the stock fell alongside other S&P 500 names like RUM Group and Kyndryl during the recent trading session. The company's high valuation, reflected in a trailing P/E of 173.1, may make the stock sensitive to broader market sentiment and volatility.